These insights deepen our understanding of how BRCA2-deficient tumors evolve, and offer alternate therapeutic opportunities, targeting A3B, UNG2, APE1, and the NF-κB axis, to suppress mutagenesis, delay resistance, and improve outcomes in BRCA2-mutant cancers. This evidence concerns the gene BRCA2 and cancer.